Oral semaglutide, from PIONEER to the Wegovy pill

Oral semaglutide is the semaglutide molecule co-formulated with an absorption enhancer, SNAC, that lets a small fraction of it cross the stomach wall. Because so little is absorbed, the doses are much larger than the weekly injection: 3 to 14 mg a day for type 2 diabetes as Rybelsus, and 25 mg a day for weight as the Wegovy pill. The tablet works only on an empty stomach with a small sip of water and a 30-minute wait. The oral Wegovy guide covers the routine. This page covers the trials.

PIONEER: the diabetes programme

The PIONEER trials led to Rybelsus, the first GLP-1 tablet, approved for type 2 diabetes in 2019. PIONEER 1, in Diabetes Care, randomised 703 adults whose diabetes was managed by diet and exercise to 3, 7 or 14 mg a day or placebo for 26 weeks. From a baseline HbA1c of 8.0 percent, HbA1c fell 0.6, 0.9 and 1.1 points more than placebo under the treatment-policy estimand, and 0.7, 1.2 and 1.4 points under the trial-product estimand, which assumes people stayed on the tablet. Weight loss was significant only at 14 mg. Between 2.3 and 7.4 percent stopped the tablet, against 2.2 percent on placebo.

PIONEER 6, in the New England Journal of Medicine in 2019, was the heart safety trial: 3,183 people with type 2 diabetes at high cardiovascular risk, followed for a median of 15.9 months. Major cardiovascular events occurred in 3.8 percent on oral semaglutide and 4.8 percent on placebo (HR 0.79, 95% CI 0.57 to 1.11). That met the test for safety, that the drug did not raise risk. It did not prove benefit, because the interval crosses 1.

SOUL: the heart outcomes trial

SOUL answered the benefit question. Published in the New England Journal of Medicine in 2025, it randomised 9,650 adults aged 50 or over with type 2 diabetes and established heart disease, chronic kidney disease or both to oral semaglutide (up to 14 mg) or placebo, on top of standard care. Over a median of 49.5 months, a major cardiovascular event (cardiovascular death, non-fatal heart attack or non-fatal stroke) occurred in 12.0 percent on oral semaglutide and 13.8 percent on placebo, a 14 percent relative reduction (HR 0.86, 95% CI 0.77 to 0.96). The confirmatory secondary outcomes did not differ significantly. Serious adverse events were slightly less common on the drug (47.9 against 50.3 percent). For the injectable equivalent in people without diabetes, see the SELECT trial.

OASIS: the weight programme

OASIS 1, in the Lancet in 2023, tested a 50 mg daily dose in 667 adults with obesity or overweight and no diabetes. At 68 weeks weight fell 15.1 percent against 2.4 percent on placebo, a difference of 12.7 points. A third of participants on the drug (34 percent) lost at least 20 percent. Gastrointestinal adverse events, mostly mild to moderate, were reported by 80 percent on the drug and 46 percent on placebo. The 50 mg dose was not the one brought to market.

OASIS 4, in the New England Journal of Medicine in 2025, tested the 25 mg dose that became the Wegovy pill. It randomised 307 adults without diabetes, 205 to oral semaglutide and 102 to placebo, with lifestyle support. At 64 weeks weight fell 13.6 percent on the drug against 2.2 percent on placebo, a difference of 11.4 points (95% CI 9.0 to 13.9). Physical function scores improved. Gastrointestinal adverse events were reported by 74.0 percent on the drug and 42.2 percent on placebo. Novo Nordisk's own announcement quoted 16.6 percent weight loss, which is the trial-product estimand for people who kept taking the tablet; the 13.6 percent figure counts everyone randomised.

That puts the 25 mg tablet in the same range as the 2.4 mg injection, which produced 14.9 percent against 2.4 percent in STEP 1 over 68 weeks. The trials differ in size, length and population, so the comparison is close rather than exact.

The Wegovy pill approval

The FDA approved oral semaglutide 25 mg as the Wegovy pill on 22 December 2025, the first oral GLP-1 for weight management, with US launch in early January 2026. According to Novo Nordisk, the approval rests on the OASIS programme and on the SELECT trial, and the label covers reducing excess weight and keeping it off, and reducing the risk of major cardiovascular events in adults with heart disease and obesity or overweight. The warnings match the injection, including the thyroid C-cell boxed warning. The dose ladder is 1.5, 4 and 9 mg for four weeks each, then 25 mg.

Pill against pill

Oral semaglutide now has a competitor with no food rules, orforglipron, sold as Foundayo. In the one head-to-head trial, ACHIEVE-3 in type 2 diabetes, orforglipron lowered HbA1c more than Rybelsus doses of oral semaglutide, while more people stopped orforglipron for side effects. There is no head-to-head weight trial of the 25 mg Wegovy pill against Foundayo. See orforglipron trials and the Foundayo guide.

Logging it

With the Wegovy pill, the dose you log is only the dose you absorbed if the routine was right. Log the tablet, the time, whether you waited 30 minutes, the step date, weight and side effects on one timeline. Peptide AI does this on the free tier; see the oral Wegovy tracker or download the app.